CBC developed a powerful creative platform for Novo Nordisk Pharmatech

Previously known as FeF Chemicals, Novo Nordisk Pharmatech had developed far beyond its history as a chemicals company to become a leading global provider of high-quality, fully traceable pharmaceutical grade Quarternary Ammonium Compounds (Quats) and Recombinant Insulin Human.

CBC’s research showed that Novo Nordisk Pharmatech should take the position as top supplier in the industry. This allowed the company to leverage the equity in the group brand, but also to express its autonomy through a differentiated visual identity.

CBC created the value proposition “Excellence. Multiplied” to convey that Novo Nordisk Pharmatech’s excellence enables the successful production and sale of hundreds of top-quality medical and personal care products across the world (vaccines, ophthalmics, nasal formulations, etc).

Our creative team also developed a powerful creative platform that emphasised the purity and precision of Pharmatech’s products and processes across a full range of on- and offline formats.

To find out more, view the case study.

About Novo Nordisk Pharmatech

Novo Nordisk Pharmatech is a global supplier of high-quality ingredients for the pharmaceutical and biopharmaceutical industries. The company specializes in producing recombinant insulin for use as an active pharmaceutical ingredient (API) in a range of drugs, including treatments for diabetes. Novo Nordisk Pharmatech’s products are manufactured to the highest standards, and the company places a strong emphasis on quality, safety, and sustainability. In addition to insulin, the company also produces a range of other pharmaceutical-grade ingredients, including human serum albumin and collagen.